Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study reveals hidden risks for virus after kidney transplant

NCT ID NCT07621835

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 236 kidney transplant patients to find out why some fail to develop immune protection against cytomegalovirus (CMV) in the first 45 days after surgery. Researchers reviewed medical records to compare patients who had a strong immune response with those who did not. The goal is to help doctors predict and manage CMV risk without needing advanced immune tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

236 people

The number who actually took part.

Started

Jan 2019

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We will conduct a retrospective, observational, multicenter cohort study of CMV-seropositive (R⁺) kidney transplant recipients who did not receive ATG induction, between 1 January, 2019 and 30 April, 2025.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years * Kidney or pancreas-kidney transplant recipients with positive CMV serology * QF-CMV test performed on day 45 post-transplant (window period between day 30 and day 60 post-transplant) * CMV PCR testing performed at least every two weeks during the first three months post-transplant Exclusion Criteria: * HIV-infected patients * Multivisceral transplant recipients * Patients scheduled to receive universal prophylaxis despite having a reactive QF-CMV result * Patients who received ATG induction therapy * Less than 6 months of post-transplant follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV reactivation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • HOSPITAL Universitario REINA SOFIA

    Córdoba, 14004, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.